Combined targeted and immunotherapy: The future of personalized medicine

Blood

Volumn 120, Issue 23, 2012, Pages 4454-4455

  Marabelle, Aurélien ^a   Caux, Christophe ^a  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; ANTIBODY; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

CANCER IMMUNOTHERAPY; IMMUNOSTIMULATION; NEOPLASM; NONHUMAN; NOTE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; DRUG EFFECT; MASTOCYTOMA;

ANIMALS; ANTIBODIES; MASTOCYTOMA; PYRIMIDINES; T-LYMPHOCYTES; THIAZOLES;

EID: 84870527415     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-455105     Document Type: Note

References (10)

1. Yang Y, Liu C, Peng W, et al. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012;120(23):4533-4543.
2. Ribas A. Tumor immunotherapy directed at PD-1. NEngl J Med. 2012;366(26):2517-2519.
3. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011 8:151-160.
4. Zitvogel L, Kroemer G. Anticancer effects of imatinib via immunostimulation. Nat Med. 2011;17(9):1050-1051.
5. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111(3):1366-1377. (Pubitemid 351213423)
6. Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma. 2012;53(6):1084-1089.
7. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol. 2010;28:57-78.
8. Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the OX40 agonist story. Immunol Rev. 2011;244(1):218-231.
9. Caux C, Zitvogel L. Recent successes of cancer immunotherapy: a new dimension in personalized medicine? Target Oncol. 2012;7(1):1-2.
10. Ménétrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W. Targeting regulatoryTcells [review]. Target Oncol. 2012;7(1):15-28.